Head-to-head evidence
Calcipotriene/Betamethasone Dipropionate Cream vs Calcipotriene/Betamethasone Dipropionate Foam
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: Vitamin D receptor + Glucocorticoid receptor · full Psoriasis pipeline
Calcipotriene/Betamethasone Dipropionate Cream · Wynzora
Marketed by MC2 Therapeutics
NCT03308799 · Phase 3 · completed
The trial randomized 794 participants to MC2-01, active calcipotriene/betamethasone, or vehicle, with investigators masked but without full double blinding. Its clinical primary endpoint favored MC2-01 based on the reported counts, but statistical significance is not stated, so the result remains unclear rather than establishing strong evidence.
Calcipotriene/Betamethasone Dipropionate Foam · Enstilar
Marketed by LEO Pharma
NCT03731091 · Phase 3 · completed
The study used randomized, quadruple-blind, active- and placebo-controlled groups with 494 participants and assessed clinical psoriasis outcomes using PGA and PASI success at Day 29. However, the primary endpoint results were not posted, so it is not possible to determine whether the comparisons met their objectives.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Calcipotriene/Betamethasone Dipropionate Cream's landscape · Calcipotriene/Betamethasone Dipropionate Foam's landscape